Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment.
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.
New Pharma Magazine aims to provoke original thinking, ideas and debate on the future of the generic, over-the-counter, biosimilar, and animal health sectors.
Cameron Loper and Brian Scrivens of MPR Associates discuss brainstorming and how it can bring a medical device to market.
Rodman & Renshaw Capital Group, Inc. will unveil an automated state-of-the-art electronic transaction platform to directly link issuers and investors.
AdvaMed 2012, the big medtech conference for industry executives, has launched its website and is calling for proposals for program panels.
Spherix has entered into definitive agreements to sell $1.15 million of shares of its common stock and warrants.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
Research indicates that the financial crisis has led to a shift in the popularity, focus, and types of deals that are being done.
Copyright © 2024 | WordPress Theme by MH Themes